Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) assessment in the identification and stratification of induction failure in patients with pediatric acute lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these patients.
Patients and Methods
Analysis included 3,113 patients who were treated in the Medical Research Council UKALL2003 multicenter randomized trial (NCT0...
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher's version
- American Society of Clinical Oncology Publisher's website
- Journal of Clinical Oncology Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Paper number:
- Copyright holder:
- American Society of Clinical Oncology
- Copyright date:
- © 2017 American Society of Clinical Oncology. All rights reserved. This is the publisher's version of the article. It is also available online from the American Society of Clinical Oncology at: [10.1200/JCO.2016.69.6278]
Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
If you are the owner of this record, you can report an update to it here: Report update to this record